Figure S1-S4, Table S1-S7 from An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian CancerNing Li, Lingying Wu, Quanren Wang et al.|Unknown|2023Cited by 0
Supplementary Figure from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II StudyXiaohua Wu, Beihua Kong, Jianqing Zhu et al.|Unknown|2023Cited by 0
Supplementary Data from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II StudyXiaohua Wu, Beihua Kong, Jianqing Zhu et al.|Unknown|2023Cited by 0
Supplementary Figure from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II StudyXiaohua Wu, Beihua Kong, Jianqing Zhu et al.|Unknown|2023Cited by 0
Supplementary Figure from Pamiparib Monotherapy for Patients with Germline <i>BRCA1/2</i>-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II StudyXiaohua Wu, Beihua Kong, Jianqing Zhu et al.|Unknown|2023Cited by 0